Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. - Wikidata - awgldk - TriplyDB

Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.

Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.

http://www.wikidata.org/entity/Q34826532

about

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.

P2860

Q34250003-0F3E107F-6323-43AE-96F6-081B9D68A324 Q35070321-E61DF68E-516A-491E-936A-1181BCBBDFDF Q41263498-01A71ADB-4191-4B37-83CD-710EB6AAF93D Q55069554-153DB3AE-F800-4D07-82A8-69CA0E01E9A5

P2860

Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.

http://www.wikidata.org/entity/Q34826532

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@ast

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@en

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@nl

type

label

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@ast

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@en

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@nl

prefLabel

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@ast

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@en

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@nl

P1433

Q34826532-A89C7C8B-E34E-41EC-A976-5461249B1964

P1476

Q34826532-949CEAA3-E272-433B-9B3B-9ED8DCA280E1

P2093

Q34826532-0A0B1F23-5D91-49FD-9A4B-F4D5B286EDEB

Q34826532-0F9CBC45-5479-46A9-B788-61211FE2B94A

Q34826532-4076AF58-A027-40CC-8BC6-ECF87B842A9A

Q34826532-436C5A7E-D955-437B-B1AE-C613028F4DDD

Q34826532-5E15F922-86E8-44C7-BF85-D2B9BDC2B1B2

Q34826532-8BFC7630-77E2-4C62-9B3F-F3C694DEC04B

Q34826532-96B3993A-E1FC-43C2-AD86-B726E3B432F0

Q34826532-B46BC2F3-5892-4528-8D17-33ABE0FCB5BA

Q34826532-D200DA86-6BA5-460A-B9EA-9EE8B5D871A5

Q34826532-E66FED2B-7E1B-488B-AEE3-04A0291720AA

P2860

Q34826532-00E511B3-C025-4905-A7B7-0671E37B1807

Q34826532-1D7C8E54-E54D-448E-938F-65F2C31A4754

Q34826532-35B85653-DF45-4144-A763-B5983A8BA81D

Q34826532-36BF8A39-4E33-43A9-8839-119B74594F54

Q34826532-38C30DE6-5894-4790-B63A-7F369E384FCE

Q34826532-3938C7B4-A8A9-484F-8613-DACD47833190

Q34826532-56E203E7-24EA-4FB1-B25C-E73D8A6A9407

Q34826532-59AB27AA-4C56-44AB-8528-177403CCEBD6

Q34826532-5AA457DE-D9BC-4B43-8257-94964DD4EAC6

Q34826532-5E730125-F0A4-4389-9986-848DCF83DB1B

P304

Q34826532-C11CB891-E29B-4C31-9A0D-3DD83B43A2A3

P31

Q34826532-724ac936-16d6-491a-8613-baa621ea2705

Q34826532-DB583F3C-A51B-45A7-8432-02BD463BC763

P356

Q34826532-41E6E3F1-FC3D-4AC6-BC92-DBA2D4B640BD

P407

Q34826532-C9CC7614-085A-4857-9196-BA38E6DD9B89

P433

Q34826532-6DEAC050-A63D-4A8F-839A-A60065028E96

P478

Q34826532-A2DBF509-4332-400C-8912-7BABB767F147

P577

Q34826532-3B7CB9E5-3CB2-49D4-8F14-32FB575BC4D6

P5875

Q34826532-122D693E-D255-40B4-B0BF-E53841F6AA92

P698

Q34826532-8303B056-6AA3-40E7-8C6F-1B4EA089DBF2

P921

Q34826532-C46EF1C2-8A92-4A0E-B6E8-E1399B11D4D6

P932

Q34826532-541558A6-EDA6-46DE-BB94-D1E9B73D7B09

P356

JOURNAL.PONE.0067929

P1433

P1476

Efficacy and safety profile of ...... lung cancer: a meta-analysis.

@en

P2093

Jianchun Gu

http://www.w3.org/2001/XMLSchema#string

Leizhen Zheng

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Lian Zhang

http://www.w3.org/2001/XMLSchema#string

Minggui Pan

http://www.w3.org/2001/XMLSchema#string

Siyu Chen

http://www.w3.org/2001/XMLSchema#string

Sungkyoung Kim

http://www.w3.org/2001/XMLSchema#string

Wei Tian

http://www.w3.org/2001/XMLSchema#string

Wenping Ding

http://www.w3.org/2001/XMLSchema#string

Xiaoping Li

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Practical methods for incorporating summary time-to-event data into meta-analysis

KRAS mutations in non-small cell lung cancer

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

e67929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0067929

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249967450

http://www.w3.org/2001/XMLSchema#string

P698

23861835

http://www.w3.org/2001/XMLSchema#string

P921

P932

3701636

http://www.w3.org/2001/XMLSchema#string